CN104080777B - 用作mogat-2抑制剂的吗啉基衍生物 - Google Patents

用作mogat-2抑制剂的吗啉基衍生物 Download PDF

Info

Publication number
CN104080777B
CN104080777B CN201380007113.8A CN201380007113A CN104080777B CN 104080777 B CN104080777 B CN 104080777B CN 201380007113 A CN201380007113 A CN 201380007113A CN 104080777 B CN104080777 B CN 104080777B
Authority
CN
China
Prior art keywords
mixture
compound
mmol
reduced pressure
under reduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380007113.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104080777A (zh
Inventor
M.R.冈萨雷斯-加西亚
M.C.费尔南德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48905712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104080777(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104080777A publication Critical patent/CN104080777A/zh
Application granted granted Critical
Publication of CN104080777B publication Critical patent/CN104080777B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380007113.8A 2012-01-31 2013-01-24 用作mogat-2抑制剂的吗啉基衍生物 Expired - Fee Related CN104080777B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12382037.5 2012-01-31
EP12382037 2012-01-31
US201261617093P 2012-03-29 2012-03-29
US61/617,093 2012-03-29
EP12382433 2012-11-06
EP12382433.6 2012-11-06
PCT/US2013/022828 WO2013116065A1 (en) 2012-01-31 2013-01-24 Novel morpholinyl derivatives useful as mogat-2 inhibitors

Publications (2)

Publication Number Publication Date
CN104080777A CN104080777A (zh) 2014-10-01
CN104080777B true CN104080777B (zh) 2015-12-09

Family

ID=48905712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380007113.8A Expired - Fee Related CN104080777B (zh) 2012-01-31 2013-01-24 用作mogat-2抑制剂的吗啉基衍生物

Country Status (23)

Country Link
US (1) US8993568B2 (https=)
EP (1) EP2809661B1 (https=)
JP (1) JP5852269B2 (https=)
KR (1) KR20140107641A (https=)
CN (1) CN104080777B (https=)
AP (1) AP2014007793A0 (https=)
AU (1) AU2013215549B2 (https=)
BR (1) BR112014018712A8 (https=)
CA (1) CA2859992A1 (https=)
CL (1) CL2014001862A1 (https=)
CO (1) CO7020914A2 (https=)
CR (1) CR20140325A (https=)
DO (1) DOP2014000177A (https=)
EA (1) EA024182B1 (https=)
ES (1) ES2571577T3 (https=)
GT (1) GT201400169A (https=)
IL (1) IL233542A0 (https=)
MX (1) MX2014008604A (https=)
PE (1) PE20141789A1 (https=)
PH (1) PH12014501712B1 (https=)
SG (1) SG11201404508XA (https=)
WO (1) WO2013116065A1 (https=)
ZA (1) ZA201405227B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体
MX2015005739A (es) 2012-11-06 2015-09-16 Lilly Co Eli Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.
US10335401B2 (en) 2015-12-21 2019-07-02 Shionogi & Co., Ltd. Non-aromatic heterocyclic derivative having MGAT2 inhibitory activity
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
CA3126334A1 (en) 2019-01-11 2020-07-16 Shionogi & Co., Ltd. Dihydropyrazolopyrazinone derivative having mgat2 inhibitory activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075070A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Sulfonamide derivatives for therapeutic use as fatty acid synthase inhibitors
CN102026976A (zh) * 2007-12-05 2011-04-20 阿斯利康(瑞典)有限公司 作为抗肥胖药物的吗啉衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
WO2000006539A1 (en) 1998-07-31 2000-02-10 Eli Lilly And Company Alkenyl sulphonamide derivatives
AU5235699A (en) 1998-07-31 2000-02-21 Eli Lilly And Company Sulfonamide derivatives
GB0408777D0 (en) 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
US8232282B2 (en) 2006-09-28 2012-07-31 Dainippon Sumitomo Pharma Co., Ltd. Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2272841A1 (en) 2008-03-28 2011-01-12 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
JP2011522006A (ja) 2008-06-04 2011-07-28 アストラゼネカ アクチボラグ 新規化合物ｖ
US20110275647A1 (en) 2009-02-23 2011-11-10 Msd K.K. Pyrimidin-4-(3h)-one derivatives
JP2014051434A (ja) 2010-12-28 2014-03-20 Dainippon Sumitomo Pharma Co Ltd 二環性ピリミジン誘導体
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Ｍｏｇａｔ−２阻害剤として有用な新規モルホリニル誘導体
AR089771A1 (es) 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
MX2015005739A (es) 2012-11-06 2015-09-16 Lilly Co Eli Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075070A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Sulfonamide derivatives for therapeutic use as fatty acid synthase inhibitors
CN102026976A (zh) * 2007-12-05 2011-04-20 阿斯利康(瑞典)有限公司 作为抗肥胖药物的吗啉衍生物

Also Published As

Publication number Publication date
EA024182B1 (ru) 2016-08-31
CR20140325A (es) 2014-08-25
JP2015504917A (ja) 2015-02-16
ZA201405227B (en) 2016-05-25
EP2809661A1 (en) 2014-12-10
HK1199024A1 (zh) 2015-06-19
AP2014007793A0 (en) 2014-07-31
US8993568B2 (en) 2015-03-31
PH12014501712A1 (en) 2014-10-13
AU2013215549A1 (en) 2014-07-17
CA2859992A1 (en) 2013-08-08
PE20141789A1 (es) 2014-11-19
MX2014008604A (es) 2014-08-22
PH12014501712B1 (en) 2014-10-13
EP2809661B1 (en) 2016-04-06
IL233542A0 (en) 2014-08-31
GT201400169A (es) 2015-08-27
BR112014018712A2 (https=) 2017-06-20
AU2013215549B2 (en) 2015-09-03
DOP2014000177A (es) 2014-08-31
WO2013116065A1 (en) 2013-08-08
JP5852269B2 (ja) 2016-02-03
CO7020914A2 (es) 2014-08-11
ES2571577T3 (es) 2016-05-26
KR20140107641A (ko) 2014-09-04
US20150005305A1 (en) 2015-01-01
BR112014018712A8 (pt) 2017-07-11
EA201491227A1 (ru) 2015-01-30
CN104080777A (zh) 2014-10-01
CL2014001862A1 (es) 2014-11-14
SG11201404508XA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
CN104080777B (zh) 用作mogat-2抑制剂的吗啉基衍生物
CN104066719B (zh) 用作mogat-2抑制剂的苄基磺酰胺衍生物
US9133122B2 (en) Amide compounds, compositions and uses thereof
RU2633694C2 (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
US20080200524A1 (en) Amide compounds as ion channel ligands and uses thereof
WO2013112323A1 (en) Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
AU2004268621A1 (en) c-Kit modulators and methods of use
JP2018536667A (ja) 重水素化されたＢｒｉｇａｔｉｎｉｂ誘導体、かかる誘導体を含む薬学的組成物、並びにそれらの使用
JP2001525399A (ja) 選択的β３アドレナリン作動性作動薬
EP2917194B1 (en) Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
MX2010012297A (es) Nuevas n-(2-amino-fenil)-acrilamidas.
JP2022115836A (ja) Ｌｐａ１受容体を拮抗するウレア化合物を有効成分として含有する医薬
TW202116741A (zh) 噻唑烷二酮衍生物以及包含其的藥物組成物
HK1199024B (en) Novel morpholinyl derivatives useful as mogat-2 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151209

Termination date: 20190124

CF01 Termination of patent right due to non-payment of annual fee